Analysts Set Audentes Therapeutics Inc (BOLD) Price Target at $34.88

Share on StockTwits

Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have received an average rating of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $34.36.

A number of analysts have recently weighed in on BOLD shares. JPMorgan Chase & Co. assumed coverage on shares of Audentes Therapeutics in a research report on Sunday, December 2nd. They set an “overweight” rating and a $23.91 price target for the company. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup decreased their price objective on shares of Audentes Therapeutics from $40.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 10th. Cowen reaffirmed a “buy” rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. Finally, Guggenheim raised shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Friday, January 11th.

BOLD stock opened at $36.66 on Tuesday. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $46.18. The company has a market cap of $1.52 billion, a PE ratio of -10.78 and a beta of 1.90.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.07. During the same quarter last year, the company posted ($0.82) EPS. Research analysts expect that Audentes Therapeutics will post -3.85 EPS for the current fiscal year.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 21,000 shares of Audentes Therapeutics stock in a transaction on Monday, February 25th. The shares were sold at an average price of $30.00, for a total value of $630,000.00. Following the completion of the transaction, the chief executive officer now owns 135,700 shares of the company’s stock, valued at $4,071,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction on Monday, February 25th. The stock was sold at an average price of $30.06, for a total transaction of $300,600.00. Following the completion of the transaction, the vice president now directly owns 28,236 shares of the company’s stock, valued at approximately $848,774.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,000 shares of company stock valued at $1,526,440. 6.60% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC lifted its stake in Audentes Therapeutics by 8.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 13,184 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 1,053 shares during the last quarter. NumerixS Investment Technologies Inc lifted its stake in Audentes Therapeutics by 1,200.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 1,200 shares during the last quarter. Teachers Advisors LLC lifted its stake in Audentes Therapeutics by 2.3% in the third quarter. Teachers Advisors LLC now owns 65,670 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 1,470 shares during the last quarter. Legal & General Group Plc lifted its stake in Audentes Therapeutics by 34.5% in the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,700 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Audentes Therapeutics by 46.1% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 1,983 shares during the last quarter.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Market Capitalization – What it Means for Investors

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.